What are the clinical presentation and management of cardiogenic shock?

Cardiogenic Shock: Clinical Presentation and Management

Cardiogenic shock is a life-threatening syndrome defined by systemic tissue hypoperfusion due to cardiac pump failure, requiring immediate recognition through the triad of hypotension (SBP <90 mmHg for >30 minutes), objective evidence of end-organ hypoperfusion (elevated lactate, altered mental status, oliguria), and underlying cardiac dysfunction—with management centered on early invasive hemodynamic assessment, multidisciplinary team-based care, and phenotype-tailored therapy. 1, 2

Clinical Presentation

Diagnostic Criteria

The diagnosis requires three essential components 2:

• Hemodynamic abnormalities: Systolic blood pressure <90 mmHg for ≥30 minutes 1
• End-organ hypoperfusion at rest: Manifested by elevated lactate, cold/clammy extremities, altered mental status, or oliguria
• Primary cardiac dysfunction: Low cardiac output (CI <2.2 L/min/m²) with cardiac power output <0.6W in severe cases 1

Clinical Phenotypes

Cardiogenic shock presents with marked heterogeneity 3:

• Cold and congested (most common): Hypoperfusion with volume overload
• Cold and dry: Hypoperfusion without congestion
• Warm and congested: Preserved perfusion with volume overload
• Warm and dry: Normotensive hypoperfusion

Mixed shock—combining pump failure with inappropriate systemic vasodilation—carries the highest mortality and demands urgent recognition 3.

Hemodynamic Profiles

Invasive hemodynamics distinguish three dominant patterns 1:

• LV-dominant CS: CPO <0.6W, PAPi >1.0, RA <15 mmHg, PCWP >15 mmHg
• RV-dominant CS: CPO <0.6W, PAPi <1.0, RA >15 mmHg, PCWP <15 mmHg
• Biventricular CS: CPO <0.6W, PAPi >1.0, RA >15 mmHg, PCWP >15 mmHg

Management Approach

Immediate Actions

1. Early invasive hemodynamic monitoring: Pulmonary artery catheter placement is essential for phenotyping and guiding therapy 1
2. Multidisciplinary shock team activation: Involving cardiology, cardiac surgery, critical care, and interventional specialists 1
3. Identify and reverse underlying cause: Acute MI requires immediate revascularization; mechanical complications need surgical evaluation

Pharmacologic Therapy by Phenotype

For LV-dominant shock with high afterload and normotensive hypoperfusion:

• Pure vasodilators (nitroprusside) reduce afterload and improve cardiac output 1
• Milrinone or dobutamine provide both inotropic support and afterload reduction 1

For RV-dominant shock:

• Intravenous or inhaled pulmonary vasodilators reduce RV afterload 1
• Minimize positive pressure ventilation, correct acidosis, and optimize oxygenation to reduce pulmonary vasoconstriction 1

For mixed shock with vasodilation:

• Vasopressors (norepinephrine) to restore systemic vascular resistance
• Inotropes cautiously, as excessive vasodilation worsens outcomes 3

Mechanical Circulatory Support Selection

Device selection must match the hemodynamic phenotype 4:

LV-dominant CS:

• IABP for mild-moderate shock
• Impella or TandemHeart for severe LV failure
• VA-ECMO for refractory shock or concurrent respiratory failure

RV-dominant CS:

• Impella RP for isolated RV failure
• VA-ECMO if progressive pulmonary hypertension (forced RV perfusion with RV-only devices risks pulmonary hemorrhage) 1

Biventricular CS:

• Protek Duo or VA-ECMO with concurrent LV/RV support 4

Critical Caveats

Contraindications to MCS 1:

• Anoxic brain injury
• Irreversible end-organ failure
• Prohibitive vascular access
• Do Not Resuscitate status

Recent observational data show increased bleeding and mortality with Impella versus IABP in propensity-matched analyses, emphasizing the need for individualized risk-benefit assessment 4. Multiple ongoing randomized trials (DanGer, ECLS-SHOCK, ECMO-CS, ANCHOR) will clarify optimal device strategies 4.

Monitoring and Reassessment

Frequent hemodynamic reassessment is mandatory, particularly in early-stage patients at risk of rapid progression 3. The SCAI classification provides a practical framework for severity stratification and longitudinal monitoring 1.

Systems-Level Care

Regionalized shock networks with dedicated cardiac intensive care units and standardized protocols have demonstrated improved outcomes 1, 5. Transfer to high-volume centers with multidisciplinary shock teams should be considered early for patients meeting criteria for refractory shock.

Key Pitfalls to Avoid

• Delayed invasive hemodynamic assessment: Clinical examination alone cannot reliably distinguish cardiogenic from other shock types 6
• Empiric MCS without phenotyping: Device selection without hemodynamic profiling increases complications without improving outcomes 4
• Overlooking mixed shock: Failure to recognize concurrent vasodilation leads to inappropriate therapy escalation 3
• Inadequate RV assessment: RV failure requires fundamentally different management than LV failure 1